Trials / Completed
CompletedNCT06685692
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Moderate Alcohol Associated Hepatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Aldeyra Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADX-629 | 125 mg twice daily for 28 days |
| DRUG | ADX-629 | 250 mg twice daily for 28 days |
Timeline
- Start date
- 2024-11-04
- Primary completion
- 2025-06-18
- Completion
- 2025-06-18
- First posted
- 2024-11-12
- Last updated
- 2025-12-12
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06685692. Inclusion in this directory is not an endorsement.